Literature DB >> 23997956

Regression Modeling and Meta-Analysis of Diagnostic Accuracy of SNP-Based Pathogenicity Detection Tools for UGT1A1 Gene Mutation.

Fakher Rahim1, Hamid Galehdari, Javad Mohammadi-Asl, Najmaldin Saki.   

Abstract

Aims. This review summarized all available evidence on the accuracy of SNP-based pathogenicity detection tools and introduced regression model based on functional scores, mutation score, and genomic variation degree. Materials and Methods. A comprehensive search was performed to find all mutations related to Crigler-Najjar syndrome. The pathogenicity prediction was done using SNP-based pathogenicity detection tools including SIFT, PHD-SNP, PolyPhen2, fathmm, Provean, and Mutpred. Overall, 59 different SNPs related to missense mutations in the UGT1A1 gene, were reviewed. Results. Comparing the diagnostic OR, our model showed high detection potential (diagnostic OR: 16.71, 95% CI: 3.38-82.69). The highest MCC and ACC belonged to our suggested model (46.8% and 73.3%), followed by SIFT (34.19% and 62.71%). The AUC analysis showed a significance overall performance of our suggested model compared to the selected SNP-based pathogenicity detection tool (P = 0.046). Conclusion. Our suggested model is comparable to the well-established SNP-based pathogenicity detection tools that can appropriately reflect the role of a disease-associated SNP in both local and global structures. Although the accuracy of our suggested model is not relatively high, the functional impact of the pathogenic mutations is highlighted at the protein level, which improves the understanding of the molecular basis of mutation pathogenesis.

Entities:  

Year:  2013        PMID: 23997956      PMCID: PMC3753762          DOI: 10.1155/2013/546909

Source DB:  PubMed          Journal:  Genet Res Int        ISSN: 2090-3162


1. Introduction

Crigler-Najjar syndrome (CNS) (MIM nos. 218800, 606785) type I and type II are inherited as autosomal recessive conditions that is resulted from mutations in the UGT1A1 gene (UGT1A1; MIM nos. 191740) [1-4]. Type I is characterized by almost complete absence of UGT1A1 enzyme activity, and these patients are refractory to phenobarbital treatment, while type II is a less severe form of deficiency [5, 6]. Patients with CNS are at permanent risk of developing severe neurologic complications such as hearing problems, mental retardation, and choreoathetosis due to severe unconjugated hyperbilirubinemia [7]. It is well known that UGT1A1 is expressed specifically in the liver and that it is difficult to perform an expression analysis directly on the patients by invasive liver biopsy but to state that the mutation causes inactivation of the enzyme you could perform an in vitro functional study by cloning the mutated cDNA of UGT1A1 in an expression vector. The constructs could be transfected in hepatic cell lines as HepG2 or HUH7. The expression analysis on these cells overexpressing the mutated forms of UGT1A1 will allow you to finally demonstrate the inactivation of the enzyme [8]. The UGT1A1 gene comprises five consecutive exons located on chromosome 2q37 by which complete or partial inactivation of any exon causes CNS. Single variations in deoxyribonucleic acid (DNA) base pairs responsible for protein, called coding which is single nucleotides polymorphism (SNP), leads to changes in amino acids that ultimately affect the protein structure and function. Different such types of SNPs include, missense mutations, nonsense, silent mutations, and splice-site mutations. The majority of missense mutations leads to considerable variation in the protein structure and function, causing the disease symptoms. Data about nonsynonymous SNPs exists in public repositories such as SWISSPROT [9], dbSNP [10], and HGVBASE [11]. Genetic methods including the detection of genes linked to the disease phenotypes and the identification of aberrant functions of these genes have, in recent years, provided worthy understanding into the biological foundations of genetic mutation [12]. The present review summarized all available evidence on the accuracy of SNP-based pathogenicity detection tools and introducing regression model based on different scores including functional scores, mutation score, and genomic variation degree and compared the results to the published clinical result.

2. Materials and Methods

2.1. SNP Data Sources and Collection

An inclusive search was done to find all CNS-related mutations. The major data repositories, including HGMD, dbSNP, SNPdbe, and Ensembl, were reviewed. All CNS-related mutations were extracted and double checked for duplicated queries and then tabulated (Table 1).
Table 1

Prediction results of SNP-based pathogenicity detection tools compared with the published results.

0SNP-IDVariantSIFTPhD-SNPPolyPhen-2fathmmProveanMutPredReferences
(1)rs74720349V3G1000010
(2)rs201984525L11P0100010
(3)rs111033541L15R1110111
(4)rs72551339H39D1111111
(5)rs140365717E56A1011110
(6)rs4148323G71R0111001
(7)rs72551340F83I0101101
(8)rs144217005V109A0101000
(9)rs140867457I116K0001100
(10)rs200734586K118N0001010
(11)rs72551341L175Q1011111
(12)rs72551342C177R0011111
(13)rs201093245Y192C1011110
(14)rs72551343R209W1011111
(15)rs144398951I215V0001000
(16)rs144721642V225M0001000
(17)rs35003977V225G0001111
(18)rs35350960P229Q0111011
(19)rs147640261T232N0001010
(20)rs57307513S250P0101010
(21)rs141950052P267R1111110
(22)rs143072292V273F1101110
(23)rs72551345G276R1111111
(24)rs72551347I294T1011111
(25)rs62625011G308E1111111
(26)rs114000345K317E0100000
(27)rs200903749I322V1011011
(28)rs17851756I322T1111110
(29)rs202035422I329T1011111
(30)rs72551348Q331R1111111
(31)rs139607673R336W1111111
(32)rs144978321S343L0111110
(33)rs149750520N344K1011100
(34)rs201372184A346V1111011
(35)rs72551351Q357R1111111
(36)rs34946978P364L0011100
(37)rs55750087R367G1011111
(38)rs72551352A368T1011111
(39)rs72551353S375F1011111
(40)rs72551354S381R1101011
(41) rs143573365 V386I0011000
(42)rs28934877N400H1111111
(43)rs72551355A401P0111111
(44)rs140613392R403H0011110
(45)rs36076514V411L0001010
(46)rs72551356K428E0011111
(47)rs202172337M441T0001000
(48)rs143033456R442C1111100
(49)rs201427749R450C1011100
(50)rs200370335R450H1011110
(51)rs114982090P451L1111110
(52)rs115410088F460L1011110
(53)rs72551358E463A1111110
(54)rs115944950E463D0111010
(55)rs72551359L474M1111000
(56)rs150687296R475H1011110
(57)rs34993780S488C0111110
(58)rs72551360V499M1011001
(59)rs199723856A511P0111010

Disease: 1; neutral: 0; references: OMIM, PMID, SNPdbe, HGMD, and Swissvar results.

2.2. Inclusion Criteria

Only UGT1A1-gene-related missense mutations were included.

2.3. Exclusion Criteria

Other types of mutation such as synonymous or nonsense were excluded.

2.4. Data Extraction

The pathogenicity prediction was done using SNP-based detection tools including SIFT [13], PHD-SNP [14], PolyPhen2 [15], fathmm [16], Provean [17], and Mutpred [18]. Then a regression model was designed using functional scores, mutation score, and genomic variation degree. For each SNP-based pathogenicity detection tool and our regression model, we extracted a 2 × 2 table including positive prediction of the disease (True Positive, TP), negative prediction as neutral (true negative, TN), positive prediction in nondisease (false positive, FP), and negative prediction in disease (false negative, FN). In order to assess the phenotypic characterization and clinical features of the disease of interest, we searched databases, including SWISSPROT [9], dbSNP [10], Ensembl [19], OMIM [20], DECIPHER [21], and HGVBASE [11]. Furthermore, we compared the results of SNP-based pathogenicity detection tools with the results of phenotypic description tools. Then we calculated the diagnostic odds ratio (diagnostic OR), which is a single indicator of test performance and varies between 0 and infinity [22].

2.5. Statistical Analysis

All the analyses were done by SPSS 16.0. A regression model was designed using three categories, including functional score [23], structural score (GV, genomic variation score) [24], and conservation score [25]. Each SNP-based pathogenicity detection tool was compared by the reference values using logistic regression. The sensitivity (Sn), specificity (Sp), accuracy (ACC), diagnostic OR, and Matthew's correlation coefficient (MCC) were calculated using the following formula: The metadisk was used to calculate individual and pooled diagnostic OR, sensitivity, specificity, negative likelihood ratio, and positive likelihood ratio [26]. We also compared the AUC (area under curve), which is a popular index of the overall performance of a test, using the summary receiver operating characteristic (SROC) curve [27].

3. Results

Overall, 59 different SNPs related to missense mutations in the UGT1A1 gene were reviewed using the designed protocol (Figure 1). Our regression model was as y = 3.39 + (−0.24 × functional score) + (−0.14 × GV score) + (−2.44 × conservation score). Comparing the diagnostic OR, our model showed high detection potential (diagnostic OR: 16.71, 95% CI: 3.38–82.69) (Figure 2). The highest MCC and ACC was belonged to our suggested model (46.8% and 73.3%), followed by SIFT (34.19% and 62.71%) (Table 2). The SROC curves reflected an acceptable and fairly good overall diagnostic performance for our suggested model compared to the SNP-based pathogenicity detection tools (Figure 3). The AUC analysis showed a significance overall performance of our suggested model compared to the selected SNP-based pathogenicity detection tool (Table 3).
Figure 1

Flowchart of searching for SNPs.

Figure 2

The individual and pooled diagnostic OR, sensitivity, specificity, negative likelihood ratio, positive likelihood ratio.

Table 2

Calculated Matthew's correlation coefficient (MCC) and accuracy (ACC) of the selected SNP-based pathogenicity detection tools and suggested model.

Detection toolsTPFPFNTNMCCACC
SIFT197151834.19%62.71%
PHD-SNP1271343.39%55.56%
PolyPhen2233201329.89%61.02%
fathmm1271343.39%55.56%
Provean206181529.99%59.32%
MutPred233201329.89%61.02%
Model262141846.80%73.33%

TP: true positive; TN: true negative; FP: false positive; FN: false negative; MCC: Matthew's correlation coefficient; ACC: accuracy.

Figure 3

The summary receiver operating characteristic (SROC) curve of the selected SNP-based pathogenicity detection tools.

Table 3

Area under curve for all the selected SNP-based pathogenicity detection tools.

Area under the curve
ToolsAreaStd. error P value95% Confidence Interval
Model.639.071.046.499.778
SIFT.527.075.716.380.675
PolyPhen2.516.076.829.367.666
PHD-SNP.571.074.345.426.716
Provean.587.074.249.442.732
Fathmm.560.075.427.413.707
Mutpred.580.075.288.433.727

*Significant, P < .05.

4. Discussion

Since the late 1990s, the initiation of research using genetic testing or molecular medicine, development of diagnostics accuracy tests, and molecular assays that measure levels of genes or specific mutations are used to provide a specific therapy for an individual's diseases. We suggested a regression model based on different scores including functional scores, conservation score, and genomic variation degree and compared the results to the published clinical result as reference. We observed the effect of a set of disease-causing missense mutations, determined from the general population. The susceptibility of Mendelian inherited disease is most frequently associated with SNPs; hence, the mechanisms by which this occurs are still poorly known. From a biological point of view, the mutated residues are important for the proper functioning of a suitable protein structure [28]. Genetic variation in phenotype of the diseases is often difficult to detect because of the complex genetic nature of these species. Using functional characteristics of the genetic mutation will provide a powerful tool to uncovering genetic traits in more complex species and provide novel insights into the molecular mechanisms of the diseases [29]. More importantly, the associations between genetic variations of SNPs of candidate genes that are selected to represent the phenotype are variable and an important feature from the disease study point of view [30]. Sensitivity was not reduced, while higher sensitivity was observed in our suggested model followed by PolyPhen2, Mutpred, and SIFT. We compared our suggested model to several well-established SNP-based pathogenicity detection tools, by which the satisfactory performance of our model and SIFT indicates the importance of a mutation position in the context of the entire protein. It is therefore reasonable to believe that analyzing the results of some SNP-based pathogenicity detection tools such as, our proposed model, SIFT and PolyPhen2 is both feasible and promising but not very excellent. Saunders and Baker [31] and Bao and Cui [32] claimed that in case of unavailability of the conservation score, structural characteristics are valuable predictors. In this study we support using the sequence conservation score which is a good predictor and showed that an acceptable level of accuracy is achieved using the conservation score. Dobson et al., used machine learning methods to measure the sequence conservation score and showed that it is the most powerful single predictor and reported a high level of accuracy using the conservation score alone [33]. They also reported higher accuracy in structural characteristics in combination with the conservation score. We also showed that structural characteristics in combination with the conservation score improves prediction accuracy and can reduce the error rate of the conservation score alone. Ng and Henikoff used sequence and/or structure to predict the effect of a missense mutation on protein function in a mathematical model and claimed that their suggested model is a good SNP-based pathogenicity detection tools [13]. Capriotti et al. [14] developed a mathematical method that started from the protein sequence information, which can predict whether a new phenotype derived from a nsSNP can be related to a genetic disease in humans. They reported more than 74% accuracy in predicting whether a single point mutation can be disease related or not. Stitziel et al. [15] introduced a tool based on the hidden Markov models (HMM) for analyzing sequence homology of SNPs and reported 68% accuracy in predicting whether a single point mutation can be disease related or not. Shihab et al. [16], described a functional analysis Through Hidden markov models software and server and reported 71% accuracy in the predicton, which was less than SIFT (74%) but equal to PolyPhen2 (71%). Choi et al. [17] developed a new algorithm, which provides a generalized approach to predict the functional effects of protein sequence variations including single or multiple amino acid substitutions and in-frame insertions and deletions. They reported 84.8% accuracy compared to SIFT (84.5%) and PolyPhen2 (84.7%) in whether predicting that mutation can be disease related or not. In the present study we observed the highest accuracy with our suggested model as 73.33% compared with SIFT (62.71%) followed by PolyPhen2 and Mutpred (61.02%, in both).

5. Conclusions

Our suggested model is comparable to the well-established SNP-based pathogenicity detection tools and can appropriately reflect the role of a disease-associated SNP in both local and global structures. A major drawback of the weighted SNP-based pathogenicity detection tools is the inherited restriction that falls within conserved protein domains. Hence, unlike other sequence-based prediction tools, which are too slow for practical use in large-scale sequencing projects, the weighted tools are computationally inexpensive and fast. Although the accuracy of our suggested model is not relatively high, the functional impact of the pathogenic mutations at the protein level is highlighted, which improves the understanding of the molecular basis of mutation pathogenesis.
  33 in total

1.  dbSNP: the NCBI database of genetic variation.

Authors:  S T Sherry; M H Ward; M Kholodov; J Baker; L Phan; E M Smigielski; K Sirotkin
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

3.  Crigler-Najjar syndrome II and pregnancy outcome.

Authors:  H Sagili; N Pramya; D Jayalaksmi; R Rani
Journal:  J Obstet Gynaecol       Date:  2012-02       Impact factor: 1.246

4.  [Crigler-Najjar syndrome: diagnosis and treatment].

Authors:  B Lodoso Torrecilla; E Palomo Atance; C Camarena Grande; Maria C Díaz Fernández; L Hierro Llanillo; A De la Vega Bueno; E Frauca Remacha; G Muñoz Bartolo; P Jara Vega
Journal:  An Pediatr (Barc)       Date:  2006-07       Impact factor: 1.500

Review 5.  Neurologic perspectives of Crigler-Najjar syndrome type I.

Authors:  M I Shevell; A Majnemer; D Schiff
Journal:  J Child Neurol       Date:  1998-06       Impact factor: 1.987

Review 6.  Genetic insights into the functional elements of language.

Authors:  Adam Szalontai; Katalin Csiszar
Journal:  Hum Genet       Date:  2013-06-08       Impact factor: 4.132

7.  DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources.

Authors:  Helen V Firth; Shola M Richards; A Paul Bevan; Stephen Clayton; Manuel Corpas; Diana Rajan; Steven Van Vooren; Yves Moreau; Roger M Pettett; Nigel P Carter
Journal:  Am J Hum Genet       Date:  2009-04-02       Impact factor: 11.025

8.  Crigler-Najjar syndrome type 2: Novel UGT1A1 mutation.

Authors:  Karippoth Mohandas Nair; Peter Lohse; Sheela Nampoothiri
Journal:  Indian J Hum Genet       Date:  2012-05

9.  Ensembl 2012.

Authors:  Paul Flicek; M Ridwan Amode; Daniel Barrell; Kathryn Beal; Simon Brent; Denise Carvalho-Silva; Peter Clapham; Guy Coates; Susan Fairley; Stephen Fitzgerald; Laurent Gil; Leo Gordon; Maurice Hendrix; Thibaut Hourlier; Nathan Johnson; Andreas K Kähäri; Damian Keefe; Stephen Keenan; Rhoda Kinsella; Monika Komorowska; Gautier Koscielny; Eugene Kulesha; Pontus Larsson; Ian Longden; William McLaren; Matthieu Muffato; Bert Overduin; Miguel Pignatelli; Bethan Pritchard; Harpreet Singh Riat; Graham R S Ritchie; Magali Ruffier; Michael Schuster; Daniel Sobral; Y Amy Tang; Kieron Taylor; Stephen Trevanion; Jana Vandrovcova; Simon White; Mark Wilson; Steven P Wilder; Bronwen L Aken; Ewan Birney; Fiona Cunningham; Ian Dunham; Richard Durbin; Xosé M Fernández-Suarez; Jennifer Harrow; Javier Herrero; Tim J P Hubbard; Anne Parker; Glenn Proctor; Giulietta Spudich; Jan Vogel; Andy Yates; Amonida Zadissa; Stephen M J Searle
Journal:  Nucleic Acids Res       Date:  2011-11-15       Impact factor: 16.971

10.  Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models.

Authors:  Hashem A Shihab; Julian Gough; David N Cooper; Peter D Stenson; Gary L A Barker; Keith J Edwards; Ian N M Day; Tom R Gaunt
Journal:  Hum Mutat       Date:  2012-11-02       Impact factor: 4.878

View more
  2 in total

1.  Clinical UGT1A1 Genetic Analysis in Pediatric Patients: Experience of a Reference Laboratory.

Authors:  Ann M Moyer; Jennifer M Skierka; Katrina E Kotzer; Michelle L Kluge; John L Black; Linnea M Baudhuin
Journal:  Mol Diagn Ther       Date:  2017-06       Impact factor: 4.074

2.  A GWAS Study on Liver Function Test Using eMERGE Network Participants.

Authors:  Bahram Namjou; Keith Marsolo; Todd Lingren; Marylyn D Ritchie; Shefali S Verma; Beth L Cobb; Cassandra Perry; Terrie E Kitchner; Murray H Brilliant; Peggy L Peissig; Kenneth M Borthwick; Marc S Williams; Jane Grafton; Gail P Jarvik; Ingrid A Holm; John B Harley
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.